News
最新消息
Singular Wings Medical, 2025 Daicel Accelerator Grand Prize Winner, Attends R&D and Technical Exchange at Tokyo HQ to Deepen PoC
2025.11.11
2025.11.11
The winner of the "Daicel Corporate Accelerator," a collaborative initiative between the century-old Japanese corporation Daicel Group and Taiwan's Industrial Technology Research Institute (ITRI), Singular Wings Medical (SWM), journeyed to the Daicel Group's Tokyo Headquarters on November 11, 2025. The visit, led and witnessed by Dr. Lewis Chen, General Director of ITRI's Commercialization and Industry Service Center (CIS), involved a Proof of Concept (PoC) and technical exchange, setting a new milestone for cross-border corporate and startup collaboration between Taiwan and Japan.
Fig. 1. Dr. Lewis Chen, General Director of ITRI's CIS, led the Singular Wings Medical and ITRI teams to the Daicel Group's Tokyo Headquarters for an in-depth exchange.
Dr. Ho emphasized that the two consecutive years of the Daicel Accelerator program have built a bridge for Taiwanese startups to open up international markets, serving as a model for Corporate Startups Engagement (CSE). Furthermore, this initiative specifically embodies ITRI's two major operational priorities: "Integrating Expertise" and "Global Deployment."
Fig. 2. Dr. Michael Ho, Partnership Director of Daicel-ITRI Accelerator, introduces ITRI's services and relevant R&D achievements.
ITRI accelerates industrialization by recruiting top talent both internally and externally, fostering cross-institutional and cross-disciplinary collaboration. This is done in alignment with the "2035 Technology Strategy and Roadmap," which focuses on Smart Living, Quality Health, Sustainable Environment, and Resilient Society as key forward-looking technologies.
This project is a vital expression of ITRI's "Global Deployment" strategy. Through the Daicel Accelerator, both parties have established a deep cooperative relationship that not only continually promotes the commercialization of innovative technologies but also successfully assists the industry in expanding global markets, enhancing Taiwan's global visibility, and achieving win-win synergy.
In addition, ITRI's CIS executes key programs such as TTA (Taiwan Tech Arena), t.Hub, TAcc+, and TREE, continuously integrating startup resources to connect startups with international markets. The Daicel Accelerator program successfully introduced alumni and teams from TTA, TAcc+, TREE, and t.Hub, accelerating the progress of the Taiwanese startup ecosystem.
Fig. 3. Dr. Lewis Chen, General Director of ITRI's CIS, delivers a speech, expressing his expectation for deeper and closer exchange between the Daicel Group, ITRI, and the Taiwanese startup ecosystem.
Fig. 4 The Singular Wings Medical team conducts a technical presentation at the Daicel Tokyo HQ, engaging in deep exchange with attending Daicel R&D and business experts.
The exchange was lively, with multiple Daicel R&D and business experts participating in in-depth discussions, expressing admiration for SWM's technical innovation and breakthroughs. Daicel experts affirmed the technology's precision and real-time capability, believing it will bring substantial synergy to Daicel's material applications and new business development. This collaboration not only speeds up technology commercialization but also helps solidify Taiwan's high-tech industry competitive advantage in the smart medical field, reflecting ITRI's goal of "Deeply Rooted in Taiwan" by driving industrial transformation through innovation.
Fig. 5 Group photo of the Singular Wings Medical team with Daicel R&D department experts, committing to jointly advance the PoC collaboration project.
During the exchange, Dr. Lewis Chen held an in-depth meeting with the Chief Technology Officer of the Daicel Group, a company built on a century of R&D focus. Both parties engaged in deep communication regarding the commercialization pathway of R&D outcomes, the synergy between accelerator startups and internal R&D, and future industry directions. This high-level dialogue focused on the strategic execution of ITRI's "Deeply Rooted in Taiwan" principle, exploring how international cooperation can consolidate high-tech industrial competitive advantages and assist industries in expanding global markets, while also echoing the "Global Deployment" corporate direction.
The Daicel CTO highly affirmed ITRI's crucial role in connecting startups with international corporations and committed to establishing closer communication and long-term cooperation with ITRI and the Taiwanese startup ecosystem, jointly exploring the immense potential of innovative materials and smart technology across various application fields.
Fig. 6 Dr. Chen Li-Wei, General Director of ITRI's CIS, meets with the Daicel Group CTO, reaching a consensus on R&D commercialization and long-term Taiwan-Japan collaboration.
ITRI's CIS will continue to act as a catalyst for the Taiwanese startup ecosystem. Through the corporate accelerator program, it will assist Taiwanese startups in cooperating with international enterprises, helping Taiwanese products market worldwide, and enhancing Taiwan's global visibility on the international stage.
The "2026 DAICEL Corporate Accelerator" program is set to launch soon, and we sincerely invite more startup teams to participate and co-create value!
Fig. 1. Dr. Lewis Chen, General Director of ITRI's CIS, led the Singular Wings Medical and ITRI teams to the Daicel Group's Tokyo Headquarters for an in-depth exchange.
Corporate Accelerator Sets CSE Collaboration Benchmark, Fulfilling ITRI's Strategy of "Integrating Expertise and Global Deployment"
The PoC Pitch session commenced with Dr. Michael Ho, Partnership Director of Daicel-ITRI Accelerator, introducing ITRI's role in industrial services and startup linkage. He expressed gratitude for the Daicel Group's affirmation of Taiwan's innovation power.Dr. Ho emphasized that the two consecutive years of the Daicel Accelerator program have built a bridge for Taiwanese startups to open up international markets, serving as a model for Corporate Startups Engagement (CSE). Furthermore, this initiative specifically embodies ITRI's two major operational priorities: "Integrating Expertise" and "Global Deployment."
Fig. 2. Dr. Michael Ho, Partnership Director of Daicel-ITRI Accelerator, introduces ITRI's services and relevant R&D achievements.
ITRI accelerates industrialization by recruiting top talent both internally and externally, fostering cross-institutional and cross-disciplinary collaboration. This is done in alignment with the "2035 Technology Strategy and Roadmap," which focuses on Smart Living, Quality Health, Sustainable Environment, and Resilient Society as key forward-looking technologies.
This project is a vital expression of ITRI's "Global Deployment" strategy. Through the Daicel Accelerator, both parties have established a deep cooperative relationship that not only continually promotes the commercialization of innovative technologies but also successfully assists the industry in expanding global markets, enhancing Taiwan's global visibility, and achieving win-win synergy.
In addition, ITRI's CIS executes key programs such as TTA (Taiwan Tech Arena), t.Hub, TAcc+, and TREE, continuously integrating startup resources to connect startups with international markets. The Daicel Accelerator program successfully introduced alumni and teams from TTA, TAcc+, TREE, and t.Hub, accelerating the progress of the Taiwanese startup ecosystem.
Fig. 3. Dr. Lewis Chen, General Director of ITRI's CIS, delivers a speech, expressing his expectation for deeper and closer exchange between the Daicel Group, ITRI, and the Taiwanese startup ecosystem.
Singular Wings Medical's Innovation Recognized, Aiding "Deeply Rooted in Taiwan" Strategy to Solidify Industrial Competitiveness
David Lee, CEO of Singular Wings Medical, detailed the features and advantages of his innovative technology during the PoC Pitch. He engaged in deep exchange with Daicel R&D, business, and technical experts, showcasing the core technology: Exclusive Non-invasive Vital Sensing Technology. SWM focuses on combining AI image recognition with advanced sensing technology to develop products that can accurately and instantly monitor human physiological data, such as blood sugar and heart rate. This innovation highly aligns with Daicel's solicitation areas, including Smart Medtech and Non-invasive vital sensing.Fig. 4 The Singular Wings Medical team conducts a technical presentation at the Daicel Tokyo HQ, engaging in deep exchange with attending Daicel R&D and business experts.
The exchange was lively, with multiple Daicel R&D and business experts participating in in-depth discussions, expressing admiration for SWM's technical innovation and breakthroughs. Daicel experts affirmed the technology's precision and real-time capability, believing it will bring substantial synergy to Daicel's material applications and new business development. This collaboration not only speeds up technology commercialization but also helps solidify Taiwan's high-tech industry competitive advantage in the smart medical field, reflecting ITRI's goal of "Deeply Rooted in Taiwan" by driving industrial transformation through innovation.
Fig. 5 Group photo of the Singular Wings Medical team with Daicel R&D department experts, committing to jointly advance the PoC collaboration project.
High-Level Dialogue Between Two Major R&D Corporations/Institutions Witnesses Startup-Corporate Exchange
The exchange was specially led and witnessed by Dr. Lewis Chen, General Director of ITRI's Commercialization and Industry Service Center.During the exchange, Dr. Lewis Chen held an in-depth meeting with the Chief Technology Officer of the Daicel Group, a company built on a century of R&D focus. Both parties engaged in deep communication regarding the commercialization pathway of R&D outcomes, the synergy between accelerator startups and internal R&D, and future industry directions. This high-level dialogue focused on the strategic execution of ITRI's "Deeply Rooted in Taiwan" principle, exploring how international cooperation can consolidate high-tech industrial competitive advantages and assist industries in expanding global markets, while also echoing the "Global Deployment" corporate direction.
The Daicel CTO highly affirmed ITRI's crucial role in connecting startups with international corporations and committed to establishing closer communication and long-term cooperation with ITRI and the Taiwanese startup ecosystem, jointly exploring the immense potential of innovative materials and smart technology across various application fields.
Fig. 6 Dr. Chen Li-Wei, General Director of ITRI's CIS, meets with the Daicel Group CTO, reaching a consensus on R&D commercialization and long-term Taiwan-Japan collaboration.
Open Innovation Model Leads to New Corporate-Startup Cooperation Opportunities, Boosting Global Marketing for Taiwanese Products
The Daicel Group emphasized that the Corporate Accelerator is a key model for promoting Open Innovation and will continue to invite global startups to participate in the future, expanding opportunities for industrial cooperation.ITRI's CIS will continue to act as a catalyst for the Taiwanese startup ecosystem. Through the corporate accelerator program, it will assist Taiwanese startups in cooperating with international enterprises, helping Taiwanese products market worldwide, and enhancing Taiwan's global visibility on the international stage.
The "2026 DAICEL Corporate Accelerator" program is set to launch soon, and we sincerely invite more startup teams to participate and co-create value!